Nov 12, 2019
Biomica Reports Positive Preliminary Results in Animal Studies in its Immuno-Oncology Program
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/evogene/biomicamed.com/wp-includes/functions.php on line 6121
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program
This is the second program to enter pre-clinical studies; In addition, Prof. David T. Rubin, joins Biomica as a scientific & medical advisor
Aims to augment current cancer therapies by altering patients’ gut microbiome to improve response
